Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia

Clinical trial NCT00142129 · COMPLETED

Trial details

NCT number: NCT00142129
Sponsor: Dana-Farber Cancer Institute
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Waldenstrom's Macroglobulinemia Lymphoplasmacytic Lymphoma

Start date: 2003-12-01
Primary completion: 2007-06-01
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.